Low and fixed dose of hydroxyurea is effective and safe in patients with HbSβ(+) thalassemia with IVS1-5(G→C) mutation.

@article{Dehury2015LowAF,
  title={Low and fixed dose of hydroxyurea is effective and safe in patients with HbSβ(+) thalassemia with IVS1-5(G→C) mutation.},
  author={Snehadhini Dehury and Prasanta Purohit and Siris Patel and Satyabrata Meher and Bipin Kishore Kullu and Lulup Kumar Sahoo and Nayan Kumar Patel and Alok Kumar Mohapatra and Kishalaya Das and Dilip Kumar Patel},
  journal={Pediatric blood & cancer},
  year={2015},
  volume={62 6},
  pages={
          1017-23
        }
}
BACKGROUND Despite compelling evidence that hydroxyurea is safe and effective in sickle cell disease, it is prescribed sparingly due to several barriers like knowledge gaps in certain genotypes, apprehension about its safety and toxicity, and limited resources. We undertook this study to find out the efficacy and safety of HU in patients with HbSβ(+) -thalassemia with IVS1-5(G→C) mutation. PROCEDURE We registered 318 patients with HbSβ(+) -thalassemia with IVS1-5(G→C) mutation. Of these, 203… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-7 OF 7 CITATIONS